View Older Stories View More Recent Stories

Apr 4, 2022 12:39PM Resorts World Las Vegas Secures First-of-its-Kind Agreement With Allergan Aesthetics
Mar 29, 2022 08:00AM AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting
Mar 21, 2022 08:30AM AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting
Mar 16, 2022 05:33PM AbbVie (ABBV) Announces FDA Approval of RINVOQ for Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Mar 16, 2022 05:29PM RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Mar 15, 2022 08:45AM Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours
Mar 15, 2022 08:00AM AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
Mar 11, 2022 05:43AM AbbVie (ABBV) and Gideon Richter Collaborate in Neuropsychiatric Diseases
Mar 11, 2022 02:00AM AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
Mar 10, 2022 08:15AM AbbVie (ABBV) Announces Positive Phase 3 Atogepant Data for the Preventive Treatment of Chronic Migraine
Mar 10, 2022 08:15AM AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
Mar 8, 2022 04:34PM AbbVie (ABBV) Resolves HUMIRA U.S. Litigation with Alvotech
Mar 8, 2022 04:32PM AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech
Mar 8, 2022 07:32AM Genmab (GMAB) and Abbvie (ABBV) Granted FDA Orphan-Drug Designation to Epcoritamab
Mar 8, 2022 07:31AM Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Mar 8, 2022 07:30AM Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Mar 1, 2022 08:30AM AbbVie to Present at the Cowen 42nd Annual Health Care Conference
Mar 1, 2022 08:01AM AbbVie (ABBV) Acquires Syndesi Therapeutics
Mar 1, 2022 08:00AM AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
Feb 28, 2022 04:16PM AbbVie (ABBV) Announces FDA Extended Review Period for SKYRIZI for the Treatment of Moderate to Severe Crohn's Disease in the U.S.
Feb 28, 2022 04:15PM AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S.
Feb 28, 2022 08:01AM AbbVie (ABBV) to Seek New Indication for IMBRUVICA in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
Feb 28, 2022 08:00AM AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
Feb 24, 2022 11:22AM Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting
Feb 24, 2022 08:01AM AbbVie (ABBV) Reports Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
Feb 24, 2022 08:00AM Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
Feb 22, 2022 08:15AM AbbVie (ABBV) Submits sNDA to U.S. FDA for cariprazine for the Adjunctive Treatment of Major Depressive Disorder
Feb 22, 2022 08:15AM AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder
Feb 17, 2022 11:33AM AbbVie Declares Quarterly Dividend
Feb 8, 2022 08:01AM AbbVie (ABBV) Announces FDA Approval of JUVEDERM VOLBELLA XC For Undereye Hollows
Feb 8, 2022 08:00AM FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows
Feb 2, 2022 07:43AM AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
Feb 1, 2022 08:45AM AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO)
Jan 24, 2022 08:00AM Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)
Jan 21, 2022 04:31PM AbbVie (ABBV) Announces U.S. FDA Approves Second Indication for SKYRIZI to Treat Adults with Active Psoriatic Arthritis
Jan 21, 2022 04:30PM U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
Jan 14, 2022 01:16PM AbbVie (ABBV) Announces FDA Approval of RINVOQ
Jan 14, 2022 01:10PM U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
Jan 11, 2022 08:45AM AbbVie (ABBV) Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025
Jan 11, 2022 08:45AM AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025
Jan 7, 2022 09:01AM AbbVie (ABBV) Submits Applications for Upadacitinib in Non-Radiographic Axial Spondyloarthritis to FDA and EMA
Jan 7, 2022 09:00AM AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
Jan 5, 2022 08:00AM AbbVie to Host Fourth-Quarter and Full-Year 2021 Earnings Conference Call
Jan 4, 2022 08:15AM AbbVie (ABBV) Granted FDA Breakthrough Therapy Designation for Telisotuzumab Vedotin
Jan 4, 2022 08:15AM AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
Jan 4, 2022 08:00AM AbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 16, 2021 08:57AM Allergan Aesthetics Completes Acquisition of Soliton
Dec 15, 2021 06:17AM AbbVie's (ABBV) RINVOQ Granted FDA Approval for Active Psoriatic Arthritis
Dec 14, 2021 06:18PM RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
Dec 10, 2021 06:30AM SpringWorks Therapeutics Inc. (SWTX) Announces Clinical Collaboration with AbbVie (ABBV) to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with R/R Multiple Myeloma
View More Recent Stories View Older Stories